Joop S.E. Laven

Joop S.E. Laven


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2004 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
JLJoop S.E. Laven
Joop S.E. Laven
AMAnnemarie G. M. G. J. Mulders
Annemarie G. M. G. J. Mulders
JVJenny A. Visser
Jenny A. Visser
ATAxel P. Themmen
Axel P. Themmen
FJFrank H. de Jong
Frank H. de Jong
BFBart C. J. M. Fauser
Bart C. J. M. Fauser
Anti-Müllerian hormone (AMH) concentrations correlate with the number of antral follicles as well as age and constitute an endocrine marker for ovarian aging. In normogonadotropic anovulatory infertile women [World Health Organization (WHO) class 2], the number of early antral follicles is usually increased. To investigate whether AMH concentrations are increased, serum levels in 128 WHO 2 women were compared with those in 41 normoovulatory premenopausal women of similar age.Serum AMH concentrations are significantly (P < 0.001) elevated in WHO 2 patients [median, 7.6 μg/liter (range, 0.1–40.0)], compared with controls [median, 2.1 μg/liter (0.1–7.4)]. In 106 patients presenting with polycystic ovaries (PCOs) (≥12 follicles/ovary measuring 2–9 mm and/or an ovarian volume > 10 ml), AMH levels were elevated [9.3 μg/liter (1.8–40.0)], compared with 22 patients without PCOs [6.4 μg/liter (0.1–22.1)] (P < 0.0001). In WHO 2 patients, AMH concentrations correlated with features characteristic for polycystic ovary syndrome such as LH concentrations (r = 0.331; P = 0.0001), testosterone levels (r = 0.477, P = 0.0001), mean ovarian volume (r = 0.421; P = 0.0001), and the number of ovarian follicles (r = 0.308; P = 0.0001). AMH levels correlated well with age in WHO 2 patients (r = −0.248; P = 0.002) as well as in controls (r = −0.465; P = 0.005). However, the relative decline in AMH with age is less pronounced in WHO 2 patients. In a subset of patients no significant correlation was found between AMH serum concentrations and the FSH response dose, the duration of stimulation, and the total number of ampoules of FSH used.In conclusion, serum AMH concentrations are elevated in WHO 2 women, especially in those patients exhibiting PCOs. Because AMH concentrations correlated well with other clinical, endocrine, and ultrasound markers associated with polycystic ovary syndrome, AMH may be used as a marker for the extent of the disease. A less pronounced AMH decrease over time in these women may suggest retarded ovarian aging. The latter hypothesis, however, should be confirmed by longitudinal studies.

24 June 2004 in Human Reproduction
Verified
Journal Article
Open access
PDF file
AMAnnemarie G.M.G.J. Mulders
Annemarie G.M.G.J. Mulders
JLJoop S.E. Laven
Joop S.E. Laven
FJFrank H. de Jong
Frank H. de Jong
ATAxel P.N. Themmen
Axel P.N. Themmen
BACKGROUND: Anti-Müllerian hormone (AMH), produced by growing pre-antral and early antral ovarian follicles, has been shown to be a useful marker for ovarian ageing. Serum AMH concentrations are elevated during reproductive life in anovulatory women, especially in those patients exhibiting polycystic ovaries (PCO). The current study was designed to investigate whether the decrease in AMH serum concentrations over time is different comparing women with normogonadotrophic anovulation [World Health Organization (WHO) group 2 (including polycystic ovary syndrome (PCOS)] and normo-ovulatory controls. METHODS and RESULTS: AMH serum levels were assessed on two occasions in 98 patients suffering from WHO 2 anovulatory infertility as well as in 41 normo-ovulatory premenopausal women. Median time interval between both visits was 2.6 years (range 0.3–9.0) for WHO 2 patients compared with 1.6 years (range 1.0–7.3) in controls. Serum AMH concentrations were significantly (P<0.0001) elevated on both occasions in WHO 2 patients (AMH1, median = 7.5 μg/l, range 0.1–35.8; and AMH2, median = 6.7 μg/l, range 0.0–30.6) compared with controls (AMH1, median = 2.1 μg/l, range 0.1–7.4; and AMH2, median = 1.3 μg/l, range 0.0–5.0). Regression analysis, corrected for age, indicated a significant relative decrease in serum AMH concentrations over time for both groups (P<0.001). However, the decline in serum AMH in WHO 2 patients was significantly less compared with controls (P=0.03). CONCLUSION: The present longitudinal study shows that serum AMH concentrations decrease over time both in women presenting with WHO 2 anovulatory infertility and in normo-ovulatory controls. The decrease in WHO 2 patients is less pronounced despite distinctly elevated concentrations. This observation may suggest retarded ovarian ageing and hence a sustained reproductive life span in these patients.

27 May 2016 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
MDMatthijs R Van Dijk
Matthijs R Van Dijk
NHNicole A Huijgen
Nicole A Huijgen
SWSten P Willemsen
Sten P Willemsen
JLJoop S.E. Laven
Joop S.E. Laven
ESEric Steegers
Eric Steegers
R.P.M. Steegers-TheunissenR.P.M. Steegers-Theunissen
R.P.M. Steegers-Theunissen
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.

12 February 2019 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
JLJoop S.E. Laven
Joop S.E. Laven
Polycystic ovary syndrome (PCOS) is the commonest endocrine abnormality in women of reproductive age typically presenting with chronic oligo- or anovulation, clinical, or biochemical hyperandrogenism and polycystic ovarian morphology (PCOM). Restoring mono-ovulation is the ultimate goal of ovulation induction and most women do respond to ovulation inducing agents causing their Follicle-stimulating hormone (FSH) levels to rise. Familial clustering and the results from twin studies strongly support an underlying genetic basis for PCOS. Recent Genome wide association studies (GWAS) have identified several genetic variants being genome wide significantly associated with PCOS. Amongst those are variants in or near the Luteinizing hormone (LH) and FSH receptor genes as well as a variant in the FSH-β gene. The aim of this review is to summarize the available evidence as to whether single nucleotide polymorphisms are able to modify the PCOS phenotype or whether they constitute a risk factor for the syndrome. Data on the role of FSHR polymorphisms in PCOS are conflicting. It seems that in large Chinese studies FSHR polymorphisms are not associated with either PCOS risk or with PCOS treatment outcome. However, in large scale studies in Caucasians these polymorphisms seem to influence the risk of having PCOS. Moreover, these studies also showed that some polymorphisms might affect some clinical features of PCOS as well as treatment outcome. Although most research has focussed on the role of FSHR polymorphisms there seems to be also some evidence showing that single nucleotide polymorphisms (SNPs) in the LHCG-Receptor as well as those in FSH-β gene might also alter the phenotype of PCOS. In conclusion most studies confirm that FSHR polymorphisms do alter the phenotype of PCOS in that they either alter the response to exogenous FSH or hat they increase the risk of having PCOS.

3 October 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DHDanielle Hiam
Danielle Hiam
AMAlba Moreno-Asso
Alba Moreno-Asso
HTHelena Jane Teede
Helena Jane Teede
JLJoop S.E. Laven
Joop S.E. Laven
NSNigel Stepto
Nigel Stepto
MGMelanie Gibson-Helm
Melanie Gibson-Helm
Polycystic Ovary Syndrome (PCOS) is a complex condition with mechanisms likely to involve the interaction between genetics and lifestyle. Familial clustering of PCOS symptoms is well documented, providing evidence for a genetic contribution to the condition. This overview aims firstly to systematically summarise the current literature surrounding genetics and PCOS, and secondly, to assess the methodological quality of current systematic reviews and identify limitations. Four databases were searched to identify candidate gene systematic reviews, and quality was assessed with the AMSTAR tool. Genome-wide association studies (GWAS) were identified by a semi structured literature search. Of the candidate gene systematic reviews, 17 were of high to moderate quality and four were of low quality. A total of 19 gene loci have been associated with risk of PCOS in GWAS, and 11 of these have been replicated across two different ancestries. Gene loci were located in the neuroendocrine, metabolic, and reproductive pathways. Overall, the gene loci with the most robust findings were THADA, FSHR, INS-VNTR, and DENND1A, that now require validation. This overview also identified limitations of the current literature and important methodological considerations for future genetic studies. Much work remains to identify causal variants and functional relevance of genes associated with PCOS.

1 August 2016 in Maturitas
Verified
Journal Article
Closed access
MGMarije Geukes
Marije Geukes
MAMariëlle P. van Aalst
Mariëlle P. van Aalst
SRSuzan J.W. Robroek
Suzan J.W. Robroek
JLJoop S.E. Laven
Joop S.E. Laven
HOHenk Oosterhof
Henk Oosterhof